Loading insider details...
Beta
Latest Form 4 (Oct 5, 2026): Exercise/Conversion of 17,750 ROIV shares, $79.2K.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Oct 5, 2026 | Roivant Sciences Ltd. (ROIV) | Exercise/Conversion | 17,750 | $79.2K |
| Sep 18, 2026 | Roivant Sciences Ltd. (ROIV) | Grant/Award | 5,054 | n/a |
| Sep 17, 2026 | Roivant Sciences Ltd. (ROIV) | Sale | 4,338 | $172.0K |
| Sep 14, 2026 | Roivant Sciences Ltd. (ROIV) | Tax Withholding | 2,179 | $89.2K |
| Jul 22, 2026 | Roivant Sciences Ltd. (ROIV) | Grant/Award | 543 | n/a |
| Jul 1, 2026 | Roivant Sciences Ltd. (ROIV) | Exercise/Conversion | 17,750 | $79.2K |
| Jun 22, 2026 | Nautilus Biotechnology, Inc. (NAUT) | Grant/Award | 45,000 | n/a |
| Apr 21, 2026 | Roivant Sciences Ltd. (ROIV) | Grant/Award | 670 | n/a |
| Mar 18, 2026 | Roivant Sciences Ltd. (ROIV) | Sale | 41,861 | $1.20M |
| Jan 23, 2026 | Roivant Sciences Ltd. (ROIV) | Grant/Award | 815 | n/a |